Age-Associated Osteoporosis Drug Discovery Services

Bone, a dynamic organ, relies on meticulously regulated processes to maintain its structure and function. The balance between bone formation, carried out by osteoblasts, and bone resorption, performed by osteoclasts, is crucial for bone homeostasis. However, as individuals age, this delicate equilibrium is disrupted. Osteoporosis (OP) is a chronic skeletal disorder characterized by diminished bone density and the deterioration of bone architecture, culminating in an elevated risk of fractures. This disease has emerged as a critical public health challenge amid global population aging, demonstrating particularly accelerated prevalence rates among postmenopausal women and adults over 65.

Fig. 1 Four stages of osteoporosis. (Abo-Elenin M, et al., 2024)

At CD BioSciences, we specialize in helping clients develop innovative therapeutics to prevent and treat age-associated osteoporosis.

Osteoporosis Drug Discovery Targeting Aging Mechanisms

Drug discovery targeting age-related hormonal changes in osteoporosis

We support clients in investigating how hormonal changes during aging, such as decreased estrogen and testosterone levels, affect bone density and strength. We help clients analyze the efficacy of estrogen and testosterone replacement therapeutics to restore hormonal balance and mitigate bone loss. By identifying potential therapeutic targets, we aim to develop drugs that modulate hormonal activity to maintain bone health.

Drug discovery targeting age-related bone changes in osteoporosis

• Targeting decreased bone formation. Aging is associated with a decline in osteoblast function, leading to decreased bone formation. We support the development of anabolic agents that promote osteoblast activity and increase bone mass. Additionally, we help clients investigate the role of growth factors such as bone morphogenetic proteins (BMPs) in stimulating osteoblast differentiation and activity.
• Targeting increased bone resorption. The imbalance between bone resorption and formation is a primary cause of osteoporosis in aging. Our experts help clients discover antiresorptive drugs that can inhibit osteoclast activity, thereby reducing bone loss in aging.
• Targeting bone microarchitecture changes. Alterations in bone microarchitecture contribute to osteoporosis in aging. We help clients develop agents that enhance bone remodeling and improve bone quality without adversely affecting bone density. Our experts can also assess changes in bone microarchitecture with advanced imaging services.

Drug discovery targeting calcium and vitamin D deficiency in aging

Our experts work closely with clients to explore innovative formulations that enhance the bioavailability and efficacy of calcium and vitamin D, enhancing optimal absorption and utilization in the body.

Features of Our Osteoporosis Drug Discovery Services

• Comprehensive understanding of aging mechanisms. We provide research services that specifically address the hormonal, metabolic, and structural changes that occur with aging, supporting clients in the development of novel therapeutics.
• Advanced drug screening services. We offer screening methods to identify promising drug candidates, accelerating the drug development process.
• Custom in vitro and in vivo models. We customize human osteoblasts (bone-forming cells), osteoclasts (bone-resorbing cells), mouse and rat models of osteoporosis, and aging animal models to assist clients in assessing the efficacy and safety of drug candidates.

At CD BioSciences, our osteoporosis drug discovery services offer a targeted and innovative approach to developing therapeutics to prevent bone loss, improve bone quality, and reduce the risk of fractures. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

1. Chandra A, Rajawat J. Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics. Int J Mol Sci, 2021, 22 (7): 3553.
2. Abo-Elenin M, et al. An Overview of Osteoporosis and Possible Treatment Approaches. Clinical & Translational Metabolism, 2024, 22.